The results suggest that CTLA-4 expression is associated with adverse prognostic factors in the IPS for advanced-stage CHL, supporting the notion that immune checkpoints play a role in cancer progression. This evidence concerns the gene CTLA4 and classic Hodgkin lymphoma.